A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT02107703
Trial Phases:	Phase III	Protocol IDs:	15362 (primary) I3Y-MC-JPBL 2013-004728-13
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT02107703

Summary

The main purpose of this study is to compare progression-free survival for women with
hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative
advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone.
Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will
last about 9 months for each participant.

For the endocrine naÃ¯ve cohort, all participants will received abemaciclib + fulvestrant.

Treatment Sites in Georgia

Harbin Clinic Cancer Center
255 West Fifth Street
Rome, GA 30165
706-528-9110
www.harbinclinic.com

Study Coordinator:

Terri Brannon
706-528-9094

Doctors:

Dilawar Khan MD

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 700
Athens, GA 30607
706-353-2990 x279
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.